Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Figure 4C HA@PPCDQ induces CD4+ effector memory T cells (TCM, CD62L+CD44+) generation at 2 weeks after boost vaccination.

ABSTRACT: C57BL/6 mice (n = 6) were immunized with PPCDQ nanovaccines or soluble protein, respectively. Splenocytes were isolated at 14 days post-boost and stained with cocktails of T cell surface markers for FCM analysis.

ORGANISM(S): Mus musculus (mouse)

SUBMITTER:

PROVIDER: S-BSST1387 | biostudies-other |

REPOSITORIES: biostudies-other

ACCESS DATA

Json Xml

Shared Molecules

Only show the datasets with similarity scores above: 0.5

Threshold

0.5

Similar Datasets

Figure 4D. HA@PPCDQ induces CD8+ effector memory T cells (TCM, CD62L+CD44+) generation at 2 weeks after boost vaccination.

Project description: Not available

| S-BSST1388 | biostudies-other

Figure 4A HA@PPCDQ induces CD4+ and CD8+ effector memory T cells (TEM, CD62L-CD44+) generation at 2 weeks after boost vaccination.

Project description: Not available

| S-BSST1386 | biostudies-other

Figure 5G. HA@PPCDQ induces higher frequency of HA-specific MBC at 2 weeks after boost vaccination.

Project description: Not available

| S-BSST1390 | biostudies-other

Figure 5D. HA@PPCDQ induces higher frequency of HA-specific GC Tfh (CD25+OX40+) cells at 1 weeks after boost vaccination.

Project description: Not available

| S-BSST1389 | biostudies-other

Figure 2A HA@PPCDQ facilitates antigen uptake in vivo.

Project description: Not available

| S-BSST1385 | biostudies-other

Comparison of naÃ¯ve, postmitotic (CD44-lo/CD62L-hi) and effector (CD44-hi/CD62L-lo) CD8+ Tcells during BMT in GVHD mice

Project description:NaÃ¯ve CD44-lo/CD62L-hi/CD8+ T cells from C3H.SW mice were compared to CD44-hi/CD82L-lo/CD8+ effector memory T cells and CD44-lo/CD62L-hi/CD8+ postmitotic T cells, using 3 biological replicates of each type of sample. The later two cells types were highly purified at day 14 after transplantation from GVHD B6/SJL mice receiving donor C3H.SW mouse-derived naive CD44-lo/CD62L-hi/CD8+ T cells and T cell-depleted bone marrow. Recipient mice had first been lethally irradiated at a dose of 10Gy in two fractions. This is a MHC-identical minor histocompatibility antigen-mismatched mouse GVHD model of human allogeneic hematopoietic stem cell transplantation. Naive T cell samples were from pools of 2 mice each, while effector memory and postmitotic T cell samples were purified from pools of T cells from 4 mice each. After RNA extraction and cleanup, biotin labeled cRNA was prepared from 600 ng total RNA, using two rounds of in vitro transcription, and hybridized to Affymetrix Mouse Genome 430A 2.0 arrays using standard techniques. Keywords: Cell type comparison 9 samples were analyzed on 9 Affymetrix microarrays to assay mRNA levels. There were 3 biological replicates of each of 3 different cell types.

2010-06-08 | E-GEOD-13743 | biostudies-arrayexpress

Comparison of naïve, postmitotic (CD44-lo/CD62L-hi) and effector (CD44-hi/CD62L-lo) CD8+ Tcells during BMT in GVHD mice

Project description:Naïve CD44-lo/CD62L-hi/CD8+ T cells from C3H.SW mice were compared to CD44-hi/CD82L-lo/CD8+ effector memory T cells and CD44-lo/CD62L-hi/CD8+ postmitotic T cells, using 3 biological replicates of each type of sample. The later two cells types were highly purified at day 14 after transplantation from GVHD B6/SJL mice receiving donor C3H.SW mouse-derived naive CD44-lo/CD62L-hi/CD8+ T cells and T cell-depleted bone marrow. Recipient mice had first been lethally irradiated at a dose of 10Gy in two fractions. This is a MHC-identical minor histocompatibility antigen-mismatched mouse GVHD model of human allogeneic hematopoietic stem cell transplantation. Naive T cell samples were from pools of 2 mice each, while effector memory and postmitotic T cell samples were purified from pools of T cells from 4 mice each. After RNA extraction and cleanup, biotin labeled cRNA was prepared from 600 ng total RNA, using two rounds of in vitro transcription, and hybridized to Affymetrix Mouse Genome 430A 2.0 arrays using standard techniques. Keywords: Cell type comparison

2010-05-21 | GSE13743 | GEO

Figure 3E and 3F. HA@PPCDQ immunization promotes neutrophil recruitment and depletion of CD169+ macrophages in spleen.

Project description: Not available

| S-BSST1384 | biostudies-other

A nanovaccine formulation of Chlamydia recombinant MOMP encapsulated in PLGA 85:15 nanoparticles augments CD4+ effector (CD44high CD62Llow) and memory (CD44high CD62Lhigh) T-cells in immunized mice.

Project description:Vaccine developmental strategies are utilizing antigens encapsulated in biodegradable polymeric nanoparticles. Here, we developed a Chlamydia nanovaccine (PLGA-rMOMP) by encapsulating its recombinant major outer membrane protein (rMOMP) in the extended-releasing and self-adjuvanting PLGA [poly (D, L-lactide-co-glycolide) (85:15)] nanoparticles. PLGA-rMOMP was small (nanometer size), round and smooth, thermally stable, and exhibited a sustained release of rMOMP. Stimulation of mouse primary dendritic cells (DCs) with PLGA-rMOMP augmented endosome processing, induced Th1 cytokines (IL-6 and IL-12p40), and expression of MHC-II and co-stimulatory (CD40, CD80, and CD86) molecules. BALB/c mice immunized with PLGA-rMOMP produced enhanced CD4+ T-cells-derived memory (CD44high CD62Lhigh), and effector (CD44high CD62Llow) phenotypes and functional antigen-specific serum IgG antibodies. In vivo biodistribution of PLGA-rMOMP revealed its localization within lymph nodes, suggesting migration from the injection site via DCs. Our data provide evidence that the PLGA (85:15) nanovaccine activates DCs and augments Chlamydia-specific rMOMP adaptive immune responses that are worthy of efficacy testing.

| S-EPMC10198673 | biostudies-literature

Transcriptomic evaluation of CD4+CD62L-CD44+FoxP3-CD45RbLo (RbLo TEM) versus CD4+CD62L+CD44-FoxP-CD45RbHi (RbHi TN) cells following activation

Project description:Deep sequencing of splenic RbLo TEM and RbHi TN cells 72 hours following anti-CD3 stimulation.

2019-06-10 | GSE89241 | GEO